Clinical observation on Edaravone in treatment of acute cerebral infarction

Objective To assess the clinical efficacy and safety of Edaravone in treatment of patients with acute cerebral infarction.Methods Sixty patients with acute cerebral infarction admitted within 48 hours of onset were enrolled in this study, they were randomly allocated into therapeutic group and control group,30 cases in each group. Patients in therapeutic group received intravenously Edaravone 30 mg in 100 ml normal saline,twice a day for 7～10 days. Patients in control group received intravenously FuFangDanShan injection of 20 ml plus normal saline 250 ml, once daily for 7～10 days. The clinical conditions of patients were evaluated according to nervous functional defect grades and activities of daily living established in 4th Conference of Cerebral Vascular Disease before and after treatment. Their clinical effectiveness and side effects were observed.Results The activities of daily living of patients were markedly improved and the grades of nervous functional defect in patients of Edaravone group were decreased distinctly in comparison with those before treatment (P0.01). The efficacy in therapeutic group was obviously superior to that of control group (P0.01). There was no significant side effect seen in patients of Edaravone group.Conclusion Edaravone is effective and safe in treatment of patients with acute cerebral infarction.